Cargando…

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis

Immune checkpoint inhibitors (ICIs) have provided tremendous clinical benefit in several cancer types. However, systemic activation of the immune system also leads to several immune-related adverse events. Of these, ICI-mediated colitis (IMC) occurs frequently and is the one with the highest absolut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Westdorp, Harm, Sweep, Mark W. D., Gorris, Mark A. J., Hoentjen, Frank, Boers-Sonderen, Marye J., van der Post, Rachel S., van den Heuvel, Michel M., Piet, Berber, Boleij, Annemarie, Bloemendal, Haiko J., de Vries, I. Jolanda M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586074/ https://www.ncbi.nlm.nih.gov/pubmed/34777387 http://dx.doi.org/10.3389/fimmu.2021.768957

Ejemplares similares

Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib
por: Sweep, Mark W. D., et al.
Publicado: (2023)

Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination
por: van Willigen, Wouter W., et al.
Publicado: (2020)

Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment
por: Kleinendorst, Simone C., et al.
Publicado: (2022)

Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy
por: Bloemendal, Martine, et al.
Publicado: (2019)

PD‐L1 in gestational trophoblastic disease: an antibody evaluation
por: Hoeijmakers, Yvonne M., et al.
Publicado: (2022)

Recent Advances and Future Perspective of DC-Based Therapy in NSCLC
por: van der Hoorn, Iris A. E., et al.
Publicado: (2021)

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management
por: Geukes Foppen, Marnix H, et al.
Publicado: (2018)

Better survival of renal cell carcinoma in patients with inflammatory bowel disease
por: Derikx, Lauranne A.A.P., et al.
Publicado: (2015)

Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination
por: van der Woude, Lieke L, et al.
Publicado: (2022)

Golimumab for the treatment of ulcerative colitis
por: Löwenberg, Mark, et al.
Publicado: (2014)

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
por: Boudewijns, Steve, et al.
Publicado: (2020)

Bacterial Oncotraits Rather than Spatial Organization Are Associated with Dysplasia in Ulcerative Colitis
por: Bruggeling, Carlijn E, et al.
Publicado: (2023)

Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients
por: Biewenga, Maaike, et al.
Publicado: (2021)

Palmar Fasciitis and Polyarthritis Syndrome: A Rare Paraneoplastic Syndrome in a Patient With Prostate Carcinoma
por: de Boer, Anouk G., et al.
Publicado: (2020)

Lower risk of severe checkpoint inhibitor toxicity in more advanced disease
por: Verheijden, Rik J, et al.
Publicado: (2020)

The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy
por: Schuurhuizen, Claudia SEW, et al.
Publicado: (2018)

Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study
por: van der Kooij, Monique K., et al.
Publicado: (2021)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Case Report: Imaging immune checkpoint inhibitor-induced yin-yang effects in the brain
por: Bol, K. F., et al.
Publicado: (2023)

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †
por: de Glas, Nienke A., et al.
Publicado: (2021)

PTEN Hamartoma Tumor Syndrome and Immune Dysregulation()()()
por: Eissing, Marc, et al.
Publicado: (2018)

Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma
por: Tolmeijer, Sofie H., et al.
Publicado: (2021)

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
por: Westdorp, Harm, et al.
Publicado: (2019)

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors
por: van Not, Olivier J., et al.
Publicado: (2023)

The Road to Infection: Host-Microbe Interactions Defining the Pathogenicity of Streptococcus bovis/Streptococcus equinus Complex Members
por: Jans, Christoph, et al.
Publicado: (2018)

Immunological responses to adjuvant vaccination with combined CD1c(+) myeloid and plasmacytoid dendritic cells in stage III melanoma patients
por: Bloemendal, Martine, et al.
Publicado: (2021)

Changes in DNA Damage Repair Gene Expression and Cell Cycle Gene Expression Do Not Explain Radioresistance in Tamoxifen-Resistant Breast Cancer
por: Post, Annemarie E. M., et al.
Publicado: (2020)

Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity
por: van Beek, Jasper J. P., et al.
Publicado: (2016)

Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens
por: Westdorp, Harm, et al.
Publicado: (2014)

Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
por: Reddy, Haritha G., et al.
Publicado: (2018)

Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition
por: Tel, Jurjen, et al.
Publicado: (2016)

Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report
por: Roelofsen, Thijs, et al.
Publicado: (2018)

Immune checkpoint inhibitor-induced colitis: A comprehensive review
por: Som, Aniruddh, et al.
Publicado: (2019)

Opportunities for immunotherapy in microsatellite instable colorectal cancer
por: Westdorp, Harm, et al.
Publicado: (2016)

Immune Checkpoint Inhibitor-Induced Colitis Presenting As Lymphocytic Colitis
por: Khan, Jaffar, et al.
Publicado: (2021)

Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2023)

Manufacturers’ views on outcome-based agreements
por: Barjestehvan Waalwijk van Doorn-Khosrovani, Sahar, et al.
Publicado: (2021)

Correction: Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
por: Reddy, Haritha G., et al.
Publicado: (2018)

Gut microbiome and checkpoint inhibitor colitis
por: Sehgal, Kanika, et al.
Publicado: (2021)

Checkpoint Inhibitor-Induced Colitis: An Update
por: Losurdo, Giuseppe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_arrsoa8lmpooi5acmup5fed67e